A £90 Million Lawsuit against Reckitt Benckiser


A £90 Million Lawsuit against Reckitt Benckiser

While preparing to sue the manufacturers of the heartburn remedy Gaviscon for almost £90 million, NHS has made serious allegations against Reckitt Benckiser saying that the firm had charged doctors with a more expensive version of the medicine when there existed a lesser expensive one.

Recently, in another case, the Office of Fair Trading had fined it £10.2 million after the officials from Reckitt Benckiser admitted breaking UK and EU legislation with the sale of the medicine to the health service.

Reckitt Benckiser's Gaviscon Original was quite a popular medicine and it was very frequently prescribed by the doctors. As its patent had to expire in 2005, other companies got a chance to offer something at a cheaper rate.

But rather than putting forward a generic name allowing cheaper versions to enter into the market, the company left doctors with no option after proposing Gaviscon Advance.

But the whole plan was exposed when an anonymous source revealed, “Reckitt cheated the Health Service. It could have saved the NHS millions of pounds. I felt it had to be exposed”.

Admitting to fail to allow competition, the company said that it had not cheated NHS in any case and it was not happy about the inappropriate language used in the internal correspondence.

Latest News

Deutsche Bank Q3 Loss may be a Record One in a Decade
Volkswagen Scandal Worries the City of Wolfsburg
Strong Component Sale and Weak Won help Samsung’s Third Quarter Profits
Is the U.S. Shale Oil Boom Heading Towards the Beginning of Its End?
Volkswagen Plans to Launch a Recall in January and Fix the Affected Diesel Cars
BOJ Keep Record Stimulus Unchanged
BP Plc will Pay $20 Billion as Penalties for the Deadly Oil Spill of 2010
Ben Bernanke says Larger Number of Executives Involved in 2008 Financial Crisis
United’s New CEO Oscar Muñoz Aims at Improving relation with Workers
The September Job Number Hint at a Sluggish Patch
First Data Launches its IPO, Targets to Raise Up to $3.7 Billion
ConAgra’s Head Quarter Move Announcement gets Positive but ‘Muted’